Loading…
ImmunityBio, Inc. is projected to rise to $8.96 by 2027, a +9% move from its current price of $8.22. IBRX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $7.92 | $8.22 | $8.53 | +0.03% |
| Jul 14 | $7.81 | $8.23 | $8.67 | +0.06% |
| Jul 15 | $7.72 | $8.23 | $8.77 | +0.09% |
| Jul 16 | $7.64 | $8.23 | $8.86 | +0.12% |
| Jul 17 | $7.58 | $8.23 | $8.94 | +0.15% |
| Jul 18 | $7.52 | $8.24 | $9.02 | +0.18% |
| Jul 19 | $7.47 | $8.24 | $9.09 | +0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.47 | $8.24 | $9.09 | +0.22% |
| Week 2 | $7.19 | $8.26 | $9.48 | +0.43% |
| Week 3 | $6.98 | $8.27 | $9.80 | +0.65% |
| Week 4 | $6.81 | $8.29 | $10.09 | +0.87% |
| Week 5 | $6.67 | $8.31 | $10.35 | +1.08% |
| Week 6 | $6.55 | $8.33 | $10.59 | +1.30% |
| Week 7 | $6.44 | $8.34 | $10.82 | +1.52% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ImmunityBio, Inc. is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
The company’s lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. ImmunityBio is based in San Diego, California.
It has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute.
ImmunityBio, Inc. (IBRX) trades at $8.76 per share and has a market capitalization of $9.17B. It is ranked 981 by market cap. The current price aligns with the forecasted 2026 average of $8.76.
The long-term forecast shows a rising price path, with averages projected to reach $16.44 by 2030, $28.56 by 2040, and $68.78 by 2050. These figures imply meaningful upside over the coming years, though they remain estimates and are not guarantees.
A major floor 34.2% below — a decisive break under it would weaken the trend.
The nearest floor, 18.2% below — buyers have tended to step in here.
The nearest ceiling, 14.8% above — a clean break opens room to run.
A major ceiling 32.0% above — clearing it would confirm fresh momentum.
Key IBRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IBRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.71 | Sell | $8.64 | Sell |
| MA 10 | $8.84 | Sell | $8.58 | Sell |
| MA 20 | $8.05 | Buy | $8.28 | Sell |
| MA 50 | $7.79 | Buy | $7.89 | Buy |
| MA 100 | $7.98 | Buy | $7.33 | Buy |
| MA 200 | $5.55 | Buy | $6.21 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.12 | Neutral |
| Stoch RSI (14) | 12.05 | Buy |
| CCI (20) | 14.07 | Neutral |
| Williams %R (14) | -54.95 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 12.30 | Buy |
| Bollinger %B (20,2) | 0.55 | Neutral |
| Stochastic %K (14) | 45.05 | Neutral |
| TRIX (15) | 0.59 | Buy |
| Awesome (5,34) | 0.94 | Buy |
| Ultimate (7,14,28) | 46.75 | Neutral |
| Momentum (10) | 0.43 | Buy |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 8.58 | Sell |
| ADX (14) | 18.66 | Neutral |
| ATR (14) | 0.27 | Info |
The sentiment is BULLISH and RSI14 sits at 60. The 50-day simple moving average is $7.71, and the 200-day simple moving average is $5.46. Support is located at $6.72 and resistance at $9.44. The 30-day range runs from $6.87 to $11.17, outlining a near-term trading corridor.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.02 | $8.22 | $10.76 | 0% | Neutral | |
| $6.90 | $8.96 | $12.45 | +9% | Neutral | |
| $6.84 | $9.24 | $13.47 | +12% | Neutral | |
| $9.05 | $12.64 | $19.11 | +54% | Bullish | |
| $9.86 | $14.18 | $22.11 | +72% | Bullish | |
| $8.95 | $13.23 | $21.19 | +61% | Bullish | |
| $9.52 | $14.43 | $23.67 | +76% | Bullish | |
| $9.27 | $14.40 | $24.14 | +75% | Bullish | |
| $9.35 | $14.85 | $25.39 | +81% | Bullish | |
| $11.52 | $18.72 | $32.59 | +128% | Bullish | |
| $12.46 | $22.42 | $42.13 | +173% | Bullish | |
| $24.24 | $52.56 | $110.08 | +539% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.02 | $8.22 | $9.65 | +0.00% |
| August 2026 | $6.83 | $8.14 | $10.02 | -0.98% |
| September 2026 | $7.02 | $8.45 | $10.56 | +3.87% |
| October 2026 | $6.85 | $8.31 | $10.51 | -1.73% |
| November 2026 | $6.65 | $8.12 | $10.38 | -2.22% |
| December 2026 | $6.78 | $8.34 | $10.76 | +2.64% |
Click any year to see its month-by-month IBRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect IBRX to range from $2.02 to $10.76 through 2026. The $8.22 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The IBRX price prediction for 2027 points to an average of $8.96 (low $6.90, high $12.45) — a potential gain of +9% on today's $8.22. A consolidation phase looks the most probable path here.
In 2028, IBRX is projected to trade between $6.84 and $13.47, averaging $9.24 — a potential gain of +12% from today's $8.22. That is up +3% on the projected 2027 average. Price action looks broadly range-bound.
ImmunityBio, Inc.'s 2029 outlook centres on $12.64, within a $9.05 to $19.11 range. That is up +37% on the projected 2028 average. That marks a +54% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, IBRX could reach as high as $22.11, with a base case around $14.18 and support toward $9.86 — roughly +72% from $8.22. Momentum favours further upside here.
Expect IBRX to range from $8.95 to $21.19 through 2031. The $13.23 average target implies a +61% move from current prices. That is -7% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
The IBRX price prediction for 2032 points to an average of $14.43 (low $9.52, high $23.67) — a potential gain of +76% on today's $8.22. Momentum favours further upside here.
In 2033, IBRX is projected to trade between $9.27 and $24.14, averaging $14.40 — a potential gain of +75% from today's $8.22. That is 0% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
ImmunityBio, Inc.'s 2034 outlook centres on $14.85, within a $9.35 to $25.39 range. That is up +3% on the projected 2033 average. That marks a +81% change versus current levels. Momentum favours further upside here.
By 2035, IBRX could reach as high as $32.59, with a base case around $18.72 and support toward $11.52 — roughly +128% from $8.22. Buyers look set to stay in control over this stretch.
Expect IBRX to range from $12.46 to $42.13 through 2040. The $22.42 average target implies a +173% move from current prices. That is up +20% on the projected 2035 average. Momentum favours further upside here.
The IBRX price prediction for 2050 points to an average of $52.56 (low $24.24, high $110.08) — a potential gain of +539% on today's $8.22. Buyers look set to stay in control over this stretch.
Investing $1,000 in IBRX today (≈ 121.654501 IBRX) could be worth
$6,394.49
+$5,394.49 (+539%) by 2050 · US Dollar
Based on the average projected IBRX price of $52.56 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IBRXwould be worth at today's price.
$1,000 invested in IBRX on Jul 10, 2025 (≈ 348.43207 IBRX) would be worth
$2,864.11
+$1,864.11 (+186.4%) today · 2.86× · US Dollar
Based on a IBRX entry price of $2.87 vs. today's $8.22.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.44 | $870.76 | -12.9% |
| 1 month ago | $6.98 | $1,177.65 | +17.8% |
| 3 months ago | $7.28 | $1,129.12 | +12.9% |
| 6 months ago | $2.59 | $3,173.75 | +217.4% |
| 1 year ago | $2.87 | $2,864.11 | +186.4% |
| All time (5.0y) ago | $11.75 | $699.57 | -30.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IBRX forecast.
Our base-case forecast reaches $16.00 around 2035.
Implied market cap at $16.00: $16.76B
The multi-year forecast outlines a rising path for ImmunityBio’s average price. In 2026 the avg is $8.76 with a min of $2.02 and a max of $11.64, yielding a 0% ROI and NEUTRAL sentiment. By 2030 the avg is $16.44 with a min of $11.44 and a max of $25.61, delivering an 87.7% ROI and BULLISH sentiment.
The trajectory continues through 2035 with an avg of $23.63 and a max of $41.08 (ROI 169.8, BULLISH), then to 2040 with an avg of $28.56 and a max of $53.56 (ROI 226.1, BULLISH), and to 2050 with an avg of $68.78 and a max of $143.70 (ROI 685.1, BULLISH). The forecast shows sentiment turning bullish from 2028 onward and remaining so through 2050, reflecting a higher long-term outlook while acknowledging these are estimates, not guarantees.
Tap a question to reveal the answer.
The forecast shows avg $16.44, min $11.44, max $25.61, ROI 87.7%, sentiment BULLISH.
Forecasts show bullish sentiment across the long term with rising averages and ROIs, but these are estimates, not guarantees.
The forecast max by 2040 is $53.56, which exceeds $50; the 2035 max is $41.08, while 2040 max is $53.56 and 2050 max is $143.70.
Current price: $8.76; Market cap: $9.17B.
2040 min $15.92, avg $28.56, max $53.56, ROI 226.1, sentiment BULLISH.
ImmunityBio, Inc. Community Discussion
0Share your ImmunityBio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.